Next 10 |
2024-06-25 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
2024-06-24 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for KROS on June 24, 2024 04:14PM ET. KROS was trading at $46.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...
2024-06-17 16:10:12 ET More on Keros Therapeutics Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for K...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patie...
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigue Data from ongoin...
2024-06-16 07:05:13 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
2024-06-15 23:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-14 15:00:00 ET More on the markets SPY Is Sub-Optimal For Long-Term Diversified Investors S&P 500 Peaks And VIX Valleys As Market Signals Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) Citi says ETFs will engulf U.S. as...
2024-06-10 12:48:37 ET Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with ...
News, Short Squeeze, Breakout and More Instantly...
Keros Therapeutics Inc. Company Name:
KROS Stock Symbol:
NASDAQ Market:
Keros Therapeutics Inc. Website:
2024-06-25 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for KROS on June 24, 2024 04:14PM ET. KROS was trading at $46.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patie...